CMAUP Plant Collective Molecular Activities

Plant Name: Agathosma bisulca

Taxonomic Information:

Plant ID: NPO23885
Plant Latin Name: Agathosma bisulca
Taxonomy Genus: Agathosma
Taxonomy Family: Rutaceae

Plant External Links:

NCBI TaxonomyDB: 1641041
Plant-of-the-World-Online: n.a.

Geographical Distribution

See the Plant Occurrence Worldwide with Latitude and Longitude Available

Collective Molecular Activities of the Plant

List of Human Proteins Collectively Targeted by the Plant

Target Activity Range: ≤ 10μM
Click Gene ID to Access Activity Profile of Individual Target

Target Class	Target Proteins
Small molecule receptor (family A GPCR)	DRD5; DRD3; DRD4; DRD1; DRD2;
Unclassified	F3; LMNA;

List of Human Cytochrome P450 Enzymes Affected by the Plant

Activity Range: ≤ 10μM
Click Gene ID to Access Activity Profile of Individual Enzyme

Cytochrome P450 Enzymes:

Detailed Information of Target Proteins

Protein Class	Gene ID	Protein Name	Uniprot ID	Target ChEMBL ID
Small molecule receptor (family A GPCR)	DRD5	Dopamine D5 receptor	P21918	CHEMBL1850
Small molecule receptor (family A GPCR)	DRD3	Dopamine D3 receptor	P35462	CHEMBL234
Small molecule receptor (family A GPCR)	DRD4	Dopamine D4 receptor	P21917	CHEMBL219
Small molecule receptor (family A GPCR)	DRD1	Dopamine D1 receptor	P21728	CHEMBL2056
Small molecule receptor (family A GPCR)	DRD2	Dopamine D2 receptor	P14416	CHEMBL217
Unclassified	F3	Coagulation factor III	P13726	CHEMBL4081
Unclassified	LMNA	Prelamin-A/C	P02545	CHEMBL1293235

Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)

Detailed Information of Enriched Gene Ontolgy

GO Type	GO Category	Enriched GO Terms	p-Value	Adjusted p-Value	Enriched Genes
BP	GO:0050896; response to stimulus	GO:0001975; response to amphetamine	6.157E-14	3.352E-10	DRD1, DRD2, DRD3, DRD4, DRD5
BP	GO:0007610; behavior	GO:0048148; behavioral response to cocaine	2.919E-11	4.539E-08	DRD1, DRD2, DRD3, DRD4
MF	GO:0060089; molecular transducer activity	GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go	1.631E-09	1.184E-06	DRD2, DRD3, DRD4
BP	GO:0009987; cellular process	GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway	3.493E-09	2.237E-06	DRD1, DRD3, DRD5
BP	GO:0009987; cellular process	GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway	3.493E-09	2.237E-06	DRD2, DRD3, DRD4
BP	GO:0050896; response to stimulus	GO:0034776; response to histamine	4.803E-09	2.988E-06	DRD2, DRD3, DRD4
BP	GO:0050896; response to stimulus	GO:0060134; prepulse inhibition	8.322E-09	4.315E-06	DRD1, DRD2, DRD3
BP	GO:0009987; cellular process	GO:0060158; phospholipase C-activating dopamine receptor signaling pathway	8.322E-09	4.315E-06	DRD1, DRD2, DRD5
BP	GO:0051179; localization	GO:0050482; arachidonic acid secretion	5.145E-08	2.197E-05	DRD2, DRD3, DRD4
BP	GO:0065007; biological regulation	GO:0006874; cellular calcium ion homeostasis	5.913E-08	2.476E-05	DRD1, DRD2, DRD3, DRD4, DRD5
BP	GO:0007610; behavior	GO:0046960; sensitization	1.126E-07	3.954E-05	DRD1, DRD5
BP	GO:0065007; biological regulation	GO:0007194; negative regulation of adenylate cyclase activity	1.439E-07	4.821E-05	DRD2, DRD3, DRD4
CC	GO:0043226; organelle	GO:0097730; non-motile cilium	1.439E-07	4.821E-05	DRD1, DRD2, DRD5
BP	GO:0065007; biological regulation	GO:0045776; negative regulation of blood pressure	3.325E-07	9.803E-05	DRD2, DRD3, DRD5
BP	GO:0009987; cellular process	GO:0060160; negative regulation of dopamine receptor signaling pathway	3.377E-07	9.803E-05	DRD2, DRD3
BP	GO:0023052; signaling	GO:0051586; positive regulation of dopamine uptake involved in synaptic transmission	3.377E-07	9.803E-05	DRD2, DRD4
BP	GO:0007610; behavior	GO:0008542; visual learning	5.005E-07	1.298E-04	DRD1, DRD2, DRD3
MF	GO:0060089; molecular transducer activity	GO:0001588; dopamine neurotransmitter receptor activity, coupled via Gs	6.752E-07	1.621E-04	DRD1, DRD5
BP	Unclassified;	GO:0021853; cerebral cortex GABAergic interneuron migration	1.125E-06	2.379E-04	DRD1, DRD2
BP	GO:0040011; locomotion	GO:0090325; regulation of locomotion involved in locomotory behavior	1.125E-06	2.379E-04	DRD2, DRD3
BP	Unclassified;	GO:0032415; regulation of sodium:proton antiporter activity	1.687E-06	3.161E-04	DRD3, DRD4
MF	Unclassified;	GO:0004872; receptor activity	1.759E-06	3.191E-04	DRD1, DRD2, DRD3, DRD4, DRD5, F3
BP	GO:0051179; localization	GO:0002028; regulation of sodium ion transport	2.645E-06	4.297E-04	DRD2, DRD3, DRD4
CC	GO:0044422; organelle part	GO:0060170; ciliary membrane	2.645E-06	4.297E-04	DRD1, DRD2, DRD5
BP	GO:0032501; multicellular organismal process	GO:0030432; peristalsis	5.059E-06	7.443E-04	DRD1, DRD2
BP	GO:0009987; cellular process	GO:0002031; G-protein coupled receptor internalization	6.182E-06	8.856E-04	DRD2, DRD3
BP	GO:0032502; developmental process	GO:0021756; striatum development	6.182E-06	8.856E-04	DRD1, DRD2
BP	GO:0007610; behavior	GO:0007625; grooming behavior	7.417E-06	1.049E-03	DRD1, DRD2
BP	GO:0009987; cellular process	GO:0050709; negative regulation of protein secretion	8.240E-06	1.143E-03	DRD2, DRD3, DRD4
BP	GO:0032501; multicellular organismal process	GO:0035815; positive regulation of renal sodium excretion	8.764E-06	1.200E-03	DRD2, DRD3
BP	GO:0007610; behavior	GO:0048149; behavioral response to ethanol	1.022E-05	1.383E-03	DRD2, DRD4
BP	GO:0023052; signaling	GO:0060292; long term synaptic depression	1.348E-05	1.768E-03	DRD1, DRD5
BP	GO:0051179; localization	GO:1901386; negative regulation of voltage-gated calcium channel activity	1.527E-05	1.991E-03	DRD2, DRD4
BP	GO:0009987; cellular process	GO:0019226; transmission of nerve impulse	1.718E-05	2.187E-03	DRD1, DRD5
BP	GO:0008152; metabolic process	GO:0042053; regulation of dopamine metabolic process	1.919E-05	2.361E-03	DRD1, DRD4
BP	GO:0032501; multicellular organismal process	GO:0045187; regulation of circadian sleep/wake cycle, sleep	1.919E-05	2.361E-03	DRD2, DRD3
BP	GO:0007610; behavior	GO:0007617; mating behavior	1.919E-05	2.361E-03	DRD1, DRD5
CC	GO:0044425; membrane part	GO:0005887; integral component of plasma membrane	3.803E-05	4.313E-03	DRD1, DRD2, DRD3, DRD4, DRD5
BP	GO:0007610; behavior	GO:0007628; adult walking behavior	3.934E-05	4.393E-03	DRD1, DRD2
BP	Unclassified;	GO:2000021; regulation of ion homeostasis	4.173E-05	4.612E-03	DRD1, DRD2, DRD3
BP	GO:0009987; cellular process	GO:0014059; regulation of dopamine secretion	4.236E-05	4.612E-03	DRD2, DRD3
BP	GO:0009987; cellular process	GO:0051896; regulation of protein kinase B signaling	4.355E-05	4.694E-03	DRD2, DRD3, F3
BP	GO:0007610; behavior	GO:0001662; behavioral fear response	4.873E-05	5.102E-03	DRD1, DRD4
BP	GO:0032501; multicellular organismal process	GO:0001659; temperature homeostasis	5.209E-05	5.350E-03	DRD1, DRD2
BP	GO:0050896; response to stimulus	GO:0043278; response to morphine	5.555E-05	5.473E-03	DRD2, DRD3
BP	GO:0050896; response to stimulus	GO:0071870; cellular response to catecholamine stimulus	6.281E-05	6.078E-03	DRD1, DRD5
BP	GO:0065007; biological regulation	GO:0007190; activation of adenylate cyclase activity	7.452E-05	6.988E-03	DRD1, DRD5
BP	GO:0040011; locomotion	GO:0030334; regulation of cell migration	8.127E-05	7.531E-03	DRD1, DRD2, F3, LMNA
BP	GO:0008152; metabolic process	GO:0031325; positive regulation of cellular metabolic process	9.309E-05	8.341E-03	DRD1, DRD2, DRD3, DRD4, DRD5, F3
BP	GO:0048511; rhythmic process	GO:0048511; rhythmic process	1.054E-04	9.200E-03	DRD2, DRD3, DRD4
MF	GO:0005488; binding	GO:0035240; dopamine binding	1.206E-15	1.313E-11	DRD1, DRD2, DRD3, DRD4, DRD5
CC	GO:0044464; cell part	GO:0042995; cell projection	7.789E-04	5.140E-02	DRD1, DRD2, DRD3, DRD5

Enriched KEGG Pathways of Target Proteins (Activity≤10μM)

Top 10 KEGG Pathways (ordered by adjusted p-value)

Detailed Information of Enriched KEGG Pathways

Pathway Category Top Level	Pathway Category Second Level	Pathway ID	Pathway Name	p-Value	Adjusted p-Value	Enriched Genes
09150 Organismal Systems	09156 Nervous system	hsa04728	Dopaminergic synapse	2.146E-10	3.649E-09	DRD1, DRD2, DRD3, DRD4, DRD5
09130 Environmental Information Processing	09133 Signaling molecules and interaction	hsa04080	Neuroactive ligand-receptor interaction	1.009E-08	8.579E-08	DRD1, DRD2, DRD3, DRD4, DRD5
09130 Environmental Information Processing	09132 Signal transduction	hsa04024	cAMP signaling pathway	3.298E-05	1.869E-04	DRD1, DRD2, DRD5
09160 Human Diseases	09164 Substance dependence	hsa05030	Cocaine addiction	1.225E-04	5.207E-04	DRD1, DRD2
09140 Cellular Processes	09144 Cellular community - eukaryotes	hsa04540	Gap junction	3.962E-04	1.347E-03	DRD1, DRD2
09130 Environmental Information Processing	09132 Signal transduction	hsa04020	Calcium signaling pathway	1.642E-03	3.489E-03	DRD1, DRD5
09160 Human Diseases	09163 Neurodegenerative diseases	hsa05012	Parkinson's disease	1.027E-03	2.910E-03	DRD1, DRD2
09160 Human Diseases	09164 Substance dependence	hsa05034	Alcoholism	1.624E-03	3.489E-03	DRD1, DRD2
09160 Human Diseases	09164 Substance dependence	hsa05031	Amphetamine addiction	2.322E-02	3.816E-02	DRD1
09150 Organismal Systems	09151 Immune system	hsa04610	Complement and coagulation cascades	2.733E-02	3.816E-02	F3

Human Diseases Associated with the Target Proteins of the Plant

Detailed Information of Human Diseases

ICD10 Disease Category	Disease Name	ICD10 Code	Associated Disease Targets (Association Ref: TTD database)
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Female sexual dysfunction	F52	DRD3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cognitive disorders	F01-F07, F04, F05, R41.3	DRD1;
I00-I99: Diseases of the circulatory system	Bleeding	I74, I80-I82	F3;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Emesis	R11	DRD3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cocaine addiction	F14.2	DRD1; DRD3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Dementia	F01-F07	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychiatric disorder	F01-F99	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychotic disorders	F20-F29	DRD1; DRD3;
I00-I99: Diseases of the circulatory system	Hypertension	I10-I16	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Schizophrenia	F20	DRD5; DRD1; DRD3;
E00-E89: Endocrine, nutritional and metabolic diseases	Type 2 diabetes	E11	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Male sexual disorders	F52	DRD3;
O00-O9A: Pregnancy, childbirth and the puerperium	Excessive bleeding following childbirth and spontaneous or elective abortion	O04	DRD1;
K00-K95: Diseases of the digestive system	Gastric motility disorder	K22.4	DRD3;
J00-J99: Diseases of the respiratory system	Adult respiratory distress syndrome	J80	F3;
C00-D49: Neoplasms	Pancreatic cancer	C25	F3;
G00-G99: Diseases of the nervous system G00-G99	Pain	G64, G90.0, R52, G89	DRD1;
G00-G99: Diseases of the nervous system G00-G99	Parkinson's disease	G20	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Substance dependence	F10-F19	DRD1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Drug abuse	F10-F19	DRD3;
C00-D49: Neoplasms	Solid tumours	C00-D48	DRD5;

Data Section	Select to Download
1. General Info & Plant Usage & Geographical Distribution
2. Human Target Proteins
3. Target Gene Ontology
4. Target KEGG Pathway
5. Related Human Diseases